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Objective To identify the most cost-effective policy for detection
and management of fetal macrosomia in late-stage pregnancy.
Design Health economic simulation model.
Setting All English NHS antenatal services.
Population Nulliparous women in the third trimester treated
within the UK NHS.
Methods A health economic simulation model was used to
compare long-term maternal–fetal health and cost outcomes
for two detection strategies (universal ultrasound scanning at
approximately 36 weeks of gestation versus selective ultrasound
scanning), combined with three management strategies
(planned caesarean section versus induction of labour versus
expectant management) of suspected fetal macrosomia.
Probabilities, costs and health outcomes were taken from
literature.
Main outcome measures Expected costs to the NHS and quality-
adjusted life-years (QALYs) gained from each strategy, calculation
of net benefit and hence identification of most cost-effective
strategy.
Results Compared with selective ultrasound, universal ultrasound
increased QALYs by 0.0038 (95% CI 0.0012–0.0076), but also
costs by £123.50 (95% CI 99.6–149.9). Overall, the health gains
were too small to justify the cost increase given current UK
thresholds cost-effective policy was selective ultrasound coupled
with induction of labour where macrosomia was suspected.
Conclusions The most cost-effective policy for detection and
management of fetal macrosomia is selective ultrasound scanning
coupled with induction of labour for all suspected cases of
macrosomia. Universal ultrasound scanning for macrosomia in
late-stage pregnancy is not cost-effective.
Keywords Economic modelling, health economics, macrosomia,
pregnancy, screening, third-trimester, ultrasound.
Tweetable abstract Universal late-pregnancy ultrasound screening
for fetal macrosomia is not warranted.
Please cite this paper as: Wastlund D, Moraitis AA, Thornton JG, Sanders J, White IR, Brocklehurst P, Smith GCS, Wilson ECF. The cost-effectiveness of
universal late-pregnancy screening for macrosomia in nulliparous women: a decision-analysis. BJOG 2019; https://doi.org/10.1111/1471-0528.15809.
Introduction
The detection and management of macrosomia, i.e. exces-
sive fetal growth, poses a challenge to maternity care.
Macrosomia is associated with increased perinatal mortality
and morbidity, e.g. shoulder dystocia leading to brachial
plexus injury, as well as increased risk of maternal
morbidity.1–3 The definition of macrosomia varies, but is
usually defined as a birthweight >4000 or >4500 g. It is dif-
ferentiated from, but closely related to, the concept of
large-for-gestational-age, which is a relative measure:
weight greater than the 90th centile for a given gestational
age.1,4 Macrosomia can only be definitively diagnosed by
weighing the infant following delivery. However,
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ultrasound scans can be used to estimate the fetal weight
antenatally, although this approach is known to have low
predictive value.1 There is no general agreement on how to
manage macrosomia if it is suspected following ultra-
sound.1,4–6 Possible interventions include scheduling an
elective Caesarean section (CS), or early induction of
labour. However, uncertainty regarding the clinical effec-
tiveness of these interventions persists.1,5 Furthermore, if
given without clinical need, intervention may cause unnec-
essary harm, e.g. neonatal respiratory morbidity, and the
increased maternal risks of CS.1,4,7,8
There is currently no national programme that couples
screening for macrosomia with a proven, disease-modifying
intervention.4,9 Currently, clinical examination of third-tri-
mester pregnancies does not routinely include ultrasound,
but women may be selected for ultrasound scanning fol-
lowing clinical suspicion of macrosomia (selective ultra-
sound). An alternative approach would be to prospectively
scan all women for macrosomia (universal ultrasound) at
around 36 weeks of gestation, but whether the benefits of
such an approach would justify the increased costs and risk
of harmful interventions is unclear. A previous study
showed only modest health benefits from universal ultra-
sound, and the cost for every prevented severe adverse out-
come was too high to justify routine scanning.10 However,
this study is now over 20 years old and only considered
one management strategy for suspected macrosomia: deliv-
ery by planned CS. Following recent research and changes
in obstetric care, we sought to re-evaluate the case for uni-
versal ultrasound screening for macrosomia.11
In this study, we identify the most cost-effective strategy
for detection and management of macrosomia in late preg-
nancy among nulliparous women in the setting of the UK
National Health Service (NHS).
Methods
Model structure
The scope of this model was limited to screening for
macrosomia rather than any other complication of preg-
nancy. To compare the cost-effectiveness of different poli-
cies for detection and management, we constructed a
decision tree simulation model using R (Figure 1).12–14
Each policy had two components: one for the detection of
macrosomia, and one for the management of suspected
macrosomia. The detection strategy was either universal
ultrasound in the third trimester (around 36 weeks of ges-
tation), or selective ultrasound, i.e. clinical examination
through abdominal palpation, where ultrasound would be
offered only where macrosomia was suspected. The man-
agement strategy for suspected macrosomia was either to
schedule an elective CS (Planned CS), induce labour
(Induction), or expectant management awaiting
spontaneous labour onset. If macrosomia was not sus-
pected, expectant management was used. There are there-
fore a total of six discrete detection/management policies.
The model structure for detection and management for
macrosomia is shown in Figure 1(A). Four different screen-
ing statuses were possible: true positives, false negatives,
false positives and true negatives. The likelihood of each
state was driven by the sensitivity and specificity of the test
used for detection, as well as the prevalence of macrosomia.
When macrosomia was suspected, the pregnancy was man-
aged according to the management strategy being evalu-
ated: planned CS, induction of labour, or expectant
management. If macrosomia was not suspected, it was
assumed that vaginal delivery would be attempted, with a
risk of emergency CS. To accurately capture the conse-
quences of a false-positive diagnosis of macrosomia, we
distinguished between expectant management when macro-
somia was suspected or not suspected; suspected macroso-
mia increased the risk of Caesarean delivery following
expectant management.8
Five neonatal delivery outcomes were possible: No com-
plications, Respiratory morbidity, Shoulder dystocia, Other
acidosis (i.e. acidosis not induced by shoulder dystocia)
and perinatal mortality. Their respective likelihoods were
affected by both screening and management strategies (see
below). The fetal delivery outcomes were then extrapolated
into long-term costs and quality-adjusted life-years
(QALYs) through the model shown in Figure 1.
Model inputs
Probabilities
For each adverse outcome (respiratory morbidity, shoulder
dystocia, other acidosis and mortality), we obtained the
baseline risk of that outcome; i.e. the risk if infant was a
non-large and non-induced neonate with vaginal delivery.
We then multiplied this risk with the relative risk of each
present risk factor (macrosomia, induction, delivery
through elective CS and delivery through emergency CS).
For technical details, see Supplementary material
(Appendix S1).
Model input parameters are shown in the Supplementary
material (Table S1). Values were identified from literature
by AM and DW, prioritising values from systematic reviews
and UK data where possible. Ideally, every input should be
based upon a systematic review, reflecting current state of
knowledge. However, resources only permitted identifica-
tion of suitable data, rather than performing a meta-analy-
sis. For this reason, sources that provided a distribution for
the likely parameter values were prioritised, so that the
overall uncertainty associated with this parameter could be
assessed through probabilistic sensitivity analysis.15 Where
multiple sources were available the source was chosen by
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consensus or through arbitration by GS. Where no credible
values for a model parameter could be identified from the
literature, AM and GS identified lower and upper limits to
the value that the parameter could reasonably assume; the
model then sampled input values from this interval using a
uniform distribution.
Macrosomia was defined as estimated fetal weight ≥ 90th
centile, i.e. the same as large-for-gestational-age. The sensi-
tivity and specificity for detection of macrosomia, as well
as the prevalence of macrosomia, were taken from the POP
study, a prospective cohort study of unselected nulliparous
women in which all women had fetal biometry at 36 weeks
of gestation, where the result of the scan was blinded.16,17
Using data from this study allowed for a comparison
between diagnostic performance of universal and selective
ultrasound. Detection with selective ultrasound was based
upon clinical suspicion before 36 weeks of gestation follow-
ing measurement of symphyseal–fundal height, and con-
firmed with a clinically indicated ultrasound.17 The baseline
risk of each adverse outcome was defined as the risk for a
normal-size neonate, where labour was not induced and
resulted in a vaginal delivery. We used odds ratios from
the literature when directly presented, otherwise we calcu-
lated unadjusted odds ratios from prevalence data.18 Odds
ratios were assumed to be log-normally distributed.
Long-term outcomes
Unit costs and health state utilities are shown in the Sup-
plementary material (Table S1). The average costs for
induction of labour and respiratory morbidity were calcu-
lated from the NHS reference costs (see Supplementary
material, Appendix S2).19 Brachial plexus injury could be
either transient or permanent, this was modelled using a b
distribution.20 We assumed that brachial plexus injury
would require the same resource usage as reported by Cul-
ligan et al., and obtained the costs for these resources from
the NHS reference costs (see Supplementary material,
Appendix S2).19,21 We assumed that all cases of nonsevere
asphyxia would be treated in the neonatal unit for 1–
3 days, but that no additional costs would accrue beyond
this. To estimate the long-term outcomes from ‘severe
anoxic brain damage’, we made the simplifying assumption
that the costs, consequences and likelihood mirrored those
of neonatal encephalopathy. Evidence shows that providing
therapeutic hypothermia reduces the likelihood of adverse
outcomes from neonatal encephalopathy, and this treat-
ment is routine clinical practice.22,23 We assumed that all
cases of neonatal encephalopathy would receive therapeutic
hypothermia, and adjusted costs and consequences from
neonatal encephalopathy accordingly; for this reason, we
reduced the likelihood of mortality and severe anoxic brain
damage following asphyxia by 11.1%.24 The costs from sev-
ere anoxic brain damage included hospital- and commu-
nity-care costs for all survivors in the cooled group as
reported by Regier et al.;22 the hospital costs were for the
first 18 months only, but we assumed that the community-
care costs after discharge would accrue annually for the
entirety of the model’s time horizon. We made the simpli-
fying assumption that the cost of death would be the same
regardless of reason.
Quality-adjusted life-years combine the utility of a
health-state with its duration, where utility is based upon
quality of life (QOL). Quality of life can be expressed as a
numeric value, where 1 is equivalent to full health and 0 is
equivalent to death.25,26 Maternal QALYs were based upon
the mode of delivery, and QOL weights were obtained
from Petrou et al.;27 these QOL weights were derived using
EQ-5D, as recommended by NICE.28,29 For surviving
Figure 1. Structure of simulation model. The figure shows the model structure, from screening to long-term health outcomes. Part A (left) shows
the pathway from screening to the mode of delivery. When macrosomia is suspected (‘T+’), the mode of delivery depends on the management
strategy as shown in part B (middle). Part C (right) shows the different delivery outcomes, and their associated long-term outcomes. BPI, brachial
plexus injury; D+, disease-positive; D, disease-negative; T+, test-positive; T, test-negative.
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infants, we calculated the expected QALYs based upon the
assumptions above; per definition, fetal QALYs were zero
for death.
Model scope
The expected cost and QALYs gained from six different
policies for screening and management of macrosomia were
calculated over a 20-year time horizon. Costs and QALYs
were discounted by 3.5% annually, as recommended by
NICE.29 Probabilistic sensitivity analysis was used to cap-
ture the overall effect of uncertainty in the model parame-
ters. Costs associated with potential litigation claims or
potential effects upon subsequent pregnancies were not
included. Results were based upon 100 000 simulations and
results presented as expected values, incremental cost and
QALYs, incremental cost-effectiveness ratios (ICERs) (the
ratio of incremental cost to incremental QALYs), and net
benefits [defined as QALYs multiplied by the willingness to
pay (WTP) for a QALY less the cost]. The WTP per QALY
threshold was assumed to be £20,000 (the lower of NICE’s
stated thresholds).29 Decision uncertainty is illustrated
using cost-effectiveness acceptability curves.29,30 The mod-
el’s sensitivity towards key parameters was explored
through one-way sensitivity analysis (see Supplementary
material, Appendix S4). Given the paucity of data relating
to maternal quality of life, an additional scenario was con-
ducted including neonatal QALYs alone. Further scenarios
explored the impact of assigning zero additional costs for
induction of labour, and assuming that induction of labour
is cost saving (due to reduced antenatal assessments).29,30
All costs are from the third-party payer (i.e. NHS) perspec-
tive, and the price year is 2016/17. Costs from other years
were inflated to the price year of the analysis using the
Hospital & Community Health Services index.31 As this is
a secondary analysis/synthesis of existing data, no patients
nor the public were involved in the study.
Results
The expected costs and QALYs for each policy are shown
in Table 1. The least expensive option is selective ultra-
sound with expectant management and the most expensive
option is universal ultrasound with planned CS. The least
effective option (in terms of QALYs gained) is universal
ultrasound with planned CS and the most effective option
is universal ultrasound with induction of labour. Three
strategies (selective US + planned CS, universal ultrasound
+ expectant management, and universal ultrasound +
planned CS) are dominated or extended-dominated by
other strategies. Taking into account the balance between
costs and outcomes (and with a WTP threshold of £20,000
per QALY), the most cost-effective strategy is selective
ultrasound plus induction of labour where macrosomia is
suspected. Although universal ultrasound plus induction is
expected to yield marginally greater QALYs (+0.002), the
added cost (+£113) yields an ICER of £52,719. This is
above the threshold and is not, therefore, cost-effective.
The expected distribution of mode of delivery and neonatal
delivery outcomes is detailed in the Supplementary material
(Appendix S3 and Table S2).
We investigated the value of universal ultrasound alone
by comparing the results for universal and selective ultra-
sound when using the same management strategy. When
the management strategy was planned CS, universal ultra-
sound was associated with a cost increase of £123.50 (95%
CI £99.60–£149.90), and a QALY increase of 0.0038 (95%
CI 0.0012–0.0076). The ICER for this strategy was £35,755
(95% CI £15,962–£98,506). The comparable ICERs for
induction of labour and expectant management were even
higher, indicating that universal ultrasound screening is
unlikely to be cost-effective.
The probability of each policy being the most cost-effec-
tive as a function of the WTP threshold is shown by the
cost-effectiveness acceptability curves (Figure 2). Selective
ultrasound coupled with induction of labour for suspected
macrosomia had the greatest chance of being cost-effective
for NICE’s recommended thresholds of £20,000–£30,000
per QALY.29 Sensitivity analysis showed that the choice of
policy was most sensitive towards the specificity of ultra-
sound (both universal and selective), maternal QOL for
delivery through elective CS, and the prevalence of macro-
somia (see Supplementary material, Appendix S4 and
Table S3). Although influential, the cost of ultrasound
screening alone appears insufficient to determine whether
universal screening would be cost-effective; analysis showed
that if other parameters remained unchanged, universal
ultrasound would only be cost-effective if the cost of ultra-
sound was £26.56 or lower.
Excluding maternal QALYs from the analysis, selective
ultrasound plus planned CS was the preferred management
strategy, compared with induction of labour, under the
base case (see Supplementary material, Table S4). No other
assumptions tested in the alternative scenarios affected the
conclusions; selective ultrasound with induction of labour
remained the preferred strategy for all other scenarios.
Discussion
Main findings
This study has compared the cost-effectiveness of different
policies for detection and management of fetal macrosomia
in late-stage pregnancy among nulliparous women. The
most cost-effective policy was selective ultrasound coupled
with induction of labour for all cases of suspected fetal
macrosomia. Although universal ultrasound scanning leads
to higher identification of suspected macrosomia, this only
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translates into modest improvements of overall long-term
health outcomes, which are not justified by the added cost
of the ultrasound scan. The expected health gain (0.003
QALYs over 20 years) is small because of both the low risk
of severe neonatal outcomes resulting from undiagnosed
macrosomia and the risk of interventions themselves caus-
ing harm.
Where macrosomia is suspected following ultrasound
scanning, intervention is generally preferred to awaiting
spontaneous labour onset. Although currently subject to
further research,32 this study found that induction of
labour is the preferred intervention. However, it is worth
noting that from the infant’s perspective alone, the best
option is an elective CS (see Supplementary material,
Table S4, scenario ‘Maternal QALYs excluded’).
Universal (rather than selective) ultrasound coupled with
induction of labour has the potential to be the most cost-
effective policy, but only at very high valuations of health
Table 1. Expected costs and QALYs per screening and management strategy
Strategy Cost (95% CI) QALY (95% CI)* ICER NMB (95% CI)
Selective ultrasound + expectant 2821 (2409–3236) 27.441 (27.262–27.621) — 546 007 (542 803–549 204)
Selective ultrasound + induction 2826 (2412–3242) 27.446 (27.267–27.626) 904 546 098 (542 890–549 298)
Selective ultrasound + planned CS 2833 (2436–3230) 27.417 (27.244–27.588) Dominated 545 501 (542 424–548 561)
Universal ultrasound + expectant 2933 (2502–3366) 27.441 (27.261–27.621) Dominated 545 884 (542 695–549 070)
Universal ultrasound + induction 2939 (2506–3374) 27.448 (27.268–27.628) 52 719 546 028 (542 829–549 214)
Universal ultrasound + planned CS 2955 (2549–3360) 27.396 (27.224–27.565) Dominated 544 956 (541 919–547 978)
NMB, net monetary benefit.
Options ordered from lowest to highest expected cost. ICERs calculated beginning with least expensive option, and comparing with next most
expensive, non-dominated option; a policy was dominated/extended-dominated if any other policy or weighted average of two policies was
associated with both lower costs and higher QALYs. Net monetary benefit (NMB) was calculated using a WTP threshold of £20,000; higher NMB
value means greater cost-effectiveness. Option with the highest expected net monetary benefit highlighted in bold. All costs and NMB are given
in pounds sterling (£).
*The maximum QALYs for two people over 20 years, discounted at 3.5%, is 29.42.
Figure 2. Cost-effectiveness acceptability curve for policies for detection and management of fetal macrosomia. Cost-effectiveness acceptability
curve showing the chance of each policy of being the most cost-effective for different levels of WTP. Policies with universal ultrasound are shown as
dashed lines and selective ultrasound as solid. Higher values for WTP imply a higher valuation of a QALY. The conventional WTP threshold for cost-
effectiveness is £20,000–£30,000 (marked in figure).29
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gain: the small added benefit does not currently justify the
cost. Sensitivity analysis shows that the relative cost-effec-
tiveness of the policies is sensitive to changes in the cost of
ultrasound scanning, as well as the costs of CS and induc-
tion of labour, and the sensitivity and specificity of ultra-
sound scanning. Hence, if the cost of the scan falls
substantially in the future, a universal scanning policy
could be cost-effective; analysis shows that this would hap-
pen at a cost below £26.56 (a cost reduction of 74.4%).
Further, macrosomia is not the only fetal complication that
can be assessed through ultrasound screening, so when
combined with a scan for other anomalies, such as breech
presentation, the marginal cost of detecting macrosomia
may be sufficiently low to render the overall policy cost-
effective. However, further work is needed to explore this.
Strengths and limitations
The strength of this study is that it evaluates strategies for
both detection and management of fetal macrosomia
jointly. There has been a lack of studies evaluating screen-
ing strategies coupled with clear evidence-based interven-
tions. Economic modelling allows us to estimate how
neonatal and maternal health outcomes would be affected
if ultrasound screening were to be routinely implemented
in clinical practice. However, the robustness of the conclu-
sions is only as strong as the data available to inform them.
Indeed, many parameters were informed by a single study,
and where no data were available we relied on expert opin-
ion. Critically, as a part of this process we elicited a range
of plausible values to represent the inherent uncertainty.
The probabilistic sensitivity analysis incorporates this
uncertainty to determine how much it affects the overall
results.
We have limited our analysis to nulliparous women. It is
unclear whether our findings could be extended to parous
women as well, especially given the absence of data on
screening performance for universal and selective ultra-
sound for this group. The economic modelling also relies
upon simplifying assumptions regarding the long-term out-
comes from the mode of delivery and fetal delivery out-
comes and did not take account of alterations to planned
place of birth following ultrasound. The interplay between
fetal macrosomia and long-term outcomes may be too
complex to capture entirely within our model; macrosomia
can lead to more complications than those explored in this
analysis. However, in the absence of more detailed data on
many of these complications, this model is still based upon
the best current understanding of macrosomia and its con-
sequences.
The probability of delivery outcomes in this analysis
relied upon the assumption of no interaction between
macrosomia and the intervention. In reality, this assump-
tion may not hold perfectly; for example, elective CS may
yield a greater relative risk reduction for babies with
macrosomia. However, data limitations made the assump-
tion necessary in order to model the relevant outcomes,
especially given the many different sources used for param-
eters. Also, the relative risks associated with both macroso-
mia and interventions were included in the analysis, even
though interactions were not modelled.
Interpretations
Our conclusion that universal ultrasound screening for fetal
macrosomia is not cost-effective aligns with previous find-
ings for macrosomia management based upon ultrasound
screening.10 Universal ultrasound screening strategies were
less cost-effective than selective ultrasound for all scenarios.
Our analysis demonstrated that universal ultrasound is
associated with improved health outcomes, but that these
gains are too small to justify its added cost.
This analysis is based in a UK NHS setting. The results
will be generalisable to other settings with similar manage-
ment policies and relative costs: current UK practice is to
offer a scan at first and second trimesters but to only offer
late-pregnancy scans where clinically indicated (our ‘selec-
tive ultrasound’ policy). Many European countries perform
a third scan around 32 weeks.33 Diagnostic effectiveness at
32 weeks for predicting complications related to macroso-
mia at delivery is likely to be poorer than at the 36–
37 weeks assumed in our analysis, given the longer interval
between the scan and time of birth.16 This would suggest
that earlier scans are even less likely to be cost-effective.
As stated above, the impact of CS on maternal QOL was
a key driver of the results. To the best of our knowledge,
the study by Petrou et al.27 is the only study that reports
maternal QOL as a function of the mode of delivery, using
an adequate time horizon and a measure for QOL recom-
mended by NICE.29 However, it reported lower QOL for
women who underwent elective CS than their counterparts
who delivered through emergency CS, a finding that
appears counterintuitive. If maternal QOL had been higher
following elective CS than emergency CS, the economic
analysis would have been more favourable towards policies
with planned CS. Against this should be weighted the
research that has shown that CS is associated with
increased risk of a range of complications in subsequent
pregnancies.34–36 These risks are not captured in our simu-
lation model because the perspective was for the current
pregnancy, but implies that managing suspected macroso-
mia through planned CS may be more detrimental than
suggested in this analysis.
This analysis has compared interventions based upon
suspicion of macrosomia alone. However, in clinical prac-
tice more factors influence antenatal management than just
whether ultrasound screening indicates fetal macrosomia.
This analysis offers valuable information for policymaking,
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but it does not rule out the use of planned CS or expectant
management in individual cases.
Conclusion
Universal ultrasound scanning in the third trimester is not
cost-effective at detecting macrosomia in nulliparous
women at current UK cost-effectiveness threshold limits. If
fetal macrosomia is suspected following ultrasound, induc-
tion of labour is likely to be the most cost-effective man-
agement option.
The conclusions are based on a single scan for macroso-
mia alone. A strategy that combines scanning for macroso-
mia with other conditions, e.g. breech presentation (and
growth restriction), might be cost-effective. Future research
should focus on whether joint screening for multiple fetal
complications would be cost-effective, as well as on the
long-term health consequences from delivery outcomes,
especially how maternal health is affected by the mode of
delivery.
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